ArticleBMC cancer2025
Quercetin inhibits gastric cancer cell proliferation and migration and is associated with the suppression of the IDO1-Kynurenine-AhR axis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the effects of quercetin, paclitaxel, and cisplatin on the proliferation and migration of gastric cancer (GC) cells, focusing on the involvement of indoleamine 2,3-dioxygenase 1 (IDO1)-mediated tryptophan metabolism.
methodsHuman GC cell lines (AGS and MKN-45) were cultured and treated with quercetin, paclitaxel, or cisplatin for 24 h according to experimental group assignments. Following treatment, cell viability was assessed using the CCK-8 assay. Apoptosis and cell cycle distribution were analyzed by flow cytometry. Cell invasion was evaluated using the Transwell assay, and migration was assessed using the wound healing assay. Quantitative PCR (qPCR) was performed to determine mRNA expression levels of IDO1, tryptophan 2,3-dioxygenase (TDO), kynurenine 3-monooxygenase (KMO), and aromatic hydrocarbon receptor (AhR). Western blotting was used to quantify protein expression of IDO1, IDO2, TDO, KMO, and AhR.
resultsTreatment with quercetin, paclitaxel, or cisplatin significantly reduced cell viability, invasion, and migration, while increasing apoptosis in AGS and MKN-45 cells. These treatments were also associated with the downregulation of IDO1, IDO2, TDO, KMO, and AhR.
conclusionQuercetin, paclitaxel, and cisplatin exert anti-proliferative and anti-migratory effects on GC cells, potentially associated with the suppression of IDO1-mediated tryptophan metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.